Medtronic Cleared for Stealth AXiS Spine Platform; Q3 Earnings on Feb. 17
Medtronic secured FDA clearance for Stealth AXiS, the first integrated planning, navigation and robotics platform for spine surgery featuring LiveAlign motion tracking. The company will report fiscal Q3 earnings Feb. 17 as investors eye strategies to generate about $500 monthly from options.
1. FDA Clearance of Stealth AXiS
Medtronic received FDA approval for its Stealth AXiS system, marking the first integrated platform that unites surgical planning, navigation and robotics for spine procedures. The system’s LiveAlign tracking provides real-time visualization of spinal motion, enhancing surgical precision and reducing workflow disruptions.
2. Upcoming Q3 Earnings and Income Strategies
The company has scheduled its fiscal third-quarter earnings release for Feb. 17 before market open. Ahead of the report, investors are evaluating option-based approaches aimed at generating roughly $500 in monthly income, reflecting growing demand for yield-focused strategies.